Add-on valganciclovir yields survival gains in glioblastoma
Use of the antiviral drug valganciclovir as an adjunct to standard therapy in patients with newly diagnosed glioblastoma appears to prolong survival, even in the presence of an unmethylated MGMT promoter gene and regardless of when given after surgery, according to the results of an experimental study.
